The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Silber Allan C since 2012.
This trader's CIK number is 1009161.
At the time of last reporting, Silber Allan C was the Executive Chairman of Point Biopharma Global Inc.. (stock ticker symbol PNT).
Also see all insider trading activities at Point Biopharma Global Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2021 | HGBL | 0 | $0 | 965,223 | $2,505,533 | 75,000 | $36,600 |
| 2016 | HGBL | 2,928,462 | $1,434,946 | 0 | $0 | 0 | $0 |
| 2015 | HGBL | 155,000 | $55,800 | 0 | $0 | 0 | $0 |
| 2014 | HGBL | 287,000 | $100,450 | 0 | $0 | 0 | $0 |
| 2012 | HGBL | 31,168 | $36,339 | 0 | $0 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2022 | PNT | 50,000 | $311,198 | 0 | $0 | 0 | $0 |
1. Heritage Global Inc. (HGBL)
2. Point Biopharma Global Inc. (PNT)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2021-09-01 | HGBL | Sale | 28,245 | 2.11 | 59,596 |
| 2021-09-02 | HGBL | Sale | 25,222 | 2.20 | 55,488 |
| 2021-08-27 | HGBL | Sale | 49,346 | 2.11 | 104,120 |
| 2021-08-30 | HGBL | Sale | 6,481 | 2.23 | 14,452 |
| 2021-08-31 | HGBL | Sale | 15,274 | 2.12 | 32,380 |
| 2021-08-26 | HGBL | Sale | 29,162 | 2.15 | 62,698 |
| 2021-08-25 | HGBL | Sale | 83,513 | 1.89 | 157,839 |
| 2021-08-24 | HGBL | Sale | 42,487 | 1.83 | 77,751 |
| 2021-08-19 | HGBL | Sale | 81,400 | 1.79 | 145,706 |
| 2021-08-13 | HGBL | Sale | 2,500 | 1.90 | 4,750 |
| 2021-03-22 | HGBL | Sale | 250,000 | 2.99 | 747,500 |
| 2021-04-09 | HGBL | Sale | 100 | 3.00 | 300 |
| 2021-04-08 | HGBL | Sale | 24,400 | 3.00 | 73,200 |
| 2021-04-07 | HGBL | Sale | 17,590 | 3.00 | 52,770 |
| 2021-03-24 | HGBL | Option Ex | 75,000 | .49 | 36,600 |
| 2021-04-05 | HGBL | Sale | 9,033 | 3.00 | 27,099 |
| 2021-04-01 | HGBL | Sale | 11,020 | 2.95 | 32,509 |
| 2021-03-19 | HGBL | Sale | 35,652 | 2.96 | 105,529 |
| 2021-03-18 | HGBL | Sale | 43,172 | 2.98 | 128,652 |
| 2021-03-17 | HGBL | Sale | 50,000 | 2.94 | 147,000 |
| 2021-03-12 | HGBL | Sale | 17,640 | 3.00 | 52,920 |
| 2021-03-11 | HGBL | Sale | 44,874 | 3.00 | 134,622 |
| 2021-03-23 | HGBL | Sale | 13,800 | 2.99 | 41,262 |
| 2021-03-24 | HGBL | Sale | 1,200 | 2.97 | 3,564 |
| 2021-03-25 | HGBL | Sale | 50,000 | 2.92 | 146,000 |
| 2021-03-26 | HGBL | Sale | 28,679 | 2.95 | 84,603 |
| 2021-03-29 | HGBL | Sale | 1,505 | 2.95 | 4,439 |
| 2021-04-06 | HGBL | Sale | 2,928 | 3.00 | 8,784 |
| 2016-12-30 | HGBL | Buy | 2,928,462 | .49 | 1,434,946 |
| 2015-05-28 | HGBL | Buy | 155,000 | .36 | 55,800 |
| 2014-12-15 | HGBL | Buy | 287,000 | .35 | 100,450 |
| 2012-12-26 | CRBN.OB | Buy | 2,005 | 1.10 | 2,205 |
| 2012-12-27 | CRBN.OB | Buy | 4,628 | 1.08 | 4,998 |
| 2012-12-28 | CRBN.OB | Buy | 6,255 | 1.10 | 6,880 |
| 2012-12-21 | CRBN.OB | Buy | 740 | 1.10 | 814 |
| 2012-12-24 | CRBN.OB | Buy | 1,513 | 1.10 | 1,664 |
| 2012-12-20 | CRBN.OB | Buy | 150 | 1.10 | 165 |
| 2012-12-19 | CRBN.OB | Buy | 935 | 1.10 | 1,028 |
| 2012-12-13 | CRBN.OB | Buy | 29 | 1.10 | 31 |
| 2012-09-28 | CRBN.OB | Buy | 13 | 1.36 | 17 |
| 2012-09-24 | CRBN.OB | Buy | 48 | 1.36 | 65 |
| 2012-09-17 | CRBN.OB | Buy | 63 | 1.36 | 85 |
| 2012-09-18 | CRBN.OB | Buy | 5 | 1.36 | 6 |
| 2012-09-14 | CRBN.OB | Buy | 1,008 | 1.36 | 1,370 |
| 2012-09-12 | CRBN.OB | Buy | 12,207 | 1.23 | 15,026 |
| 2012-09-13 | CRBN.OB | Buy | 1,000 | 1.36 | 1,360 |
| 2012-09-05 | CRBN.OB | Buy | 250 | 1.10 | 275 |
| 2012-08-30 | CRBN.OB | Buy | 1 | 1.10 | 1 |
| 2012-08-29 | CRBN.OB | Buy | 318 | 1.10 | 349 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2022-11-17 | PNT | Buy | 27,603 | 6.00 | 165,618 |
| 2022-11-18 | PNT | Buy | 22,397 | 6.50 | 145,580 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Silber Allan C (Executive Chairman of Point Biopharma Global Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.